Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1
Anti-retrovirals for reducing the risk of mother-to-child transmission of HIV infection
Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Anti-retrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; 7:CD003510.
Time to viral load suppression in antiretroviral-naive and-experienced HIV-infected pregnant women on highly active antiretroviral therapy: Implications for pregnant women presenting late in gestation
Aziz N, Sokoloff A, Kornak J, et al. Time to viral load suppression in antiretroviral-naive and-experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation. BJOG 2013; 120:1534-1547.
Effect of pregnancy and the postpartum period on adherence to anti-retroviral therapy among HIV-infected women established on treatment
Henegar CE, Westreich DJ, Maskew M, et al. Effect of pregnancy and the postpartum period on adherence to anti-retroviral therapy among HIV-infected women established on treatment. J Acquir Immune Defic Syndr 2015; 68:477-480.
Factors associated with lack of viral suppression at delivery among highly active antiretro-viral therapy-naive women with HIV: A cohort study
Katz IT, Leister E, Kacanek D, et al. Factors associated with lack of viral suppression at delivery among highly active antiretro-viral therapy-naive women with HIV: a cohort study. Ann Intern Med 2015; 162:90-99.
Achieving rapid reduction of HIV-1 viral load in HIV-positive pregnant women close to term-an obstetric/medical emergency: A review of three cases
Adeyemo A, Wood C, Govind A. Achieving rapid reduction of HIV-1 viral load in HIV-positive pregnant women close to term-an obstetric/medical emergency: a review of three cases. Int J STD AIDS 2013; 24:591-592.
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy
Pinnetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010; 65:2050-2052.
Dolutegravir: A new integrase strand transfer inhibitor for the treatment of HIV
Shah BM, Schafer JJ, Desimone JA Jr. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy 2014; 34:506-520.
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-näive HIV-infected individuals in three randomized trials
Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-näive HIV-infected individuals in three randomized trials. AIDS 2015; 29:167-174.
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-näive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study
Clotet B, Feinberg J, van Lunzen J, et al., for ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-näive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. Lancet 2014; 383:2222-2231.
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study
Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther 2014; doi: 10.3851/IMP2878.
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://aidsinfo.nih.gov/guidelines. [Accessed 16 March 2015]
Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Updated December 18, 2014 [Accessed 8 August 2015]
Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Updated December 18, 2014. http://www.salute.gov. it/imgs/C-17-pubblicazioni-2261-allegato.pdf. [Accessed 8 August 2015]
14
84916594178
Preventing unintended pregnancy and HIV transmission: Effects of the HIV treatment cascade on contraceptive use and choice in rural KwaZulu-Natal
Raifman J, Chetty T, Tanser F, et al. Preventing unintended pregnancy and HIV transmission: effects of the HIV treatment cascade on contraceptive use and choice in rural KwaZulu-Natal. J Acquir Immune Defic Syndr 2014; 67 (Suppl 4):S218-S227.
Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Use of specific antiretroviral regimens among HIV-infected women in Italy at time of conception: 2001-2011
Floridia M, Ravizza M, Guaraldi G, et al. Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Use of specific antiretroviral regimens among HIV-infected women in Italy at time of conception: 2001-2011. Aids Patient Care STDS 2012; 26:439-443.
